2/24
04:09 pm
howl
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
High
Report
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
1/23
05:09 am
howl
Werewolf Therapeutics (NASDAQ:HOWL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Werewolf Therapeutics (NASDAQ:HOWL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
04:46 am
howl
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results [Yahoo! Finance]
Medium
Report
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results [Yahoo! Finance]